Immunotherapy holds the key to cancer treatment and prevention in constitutional mismatch repair deficiency (CMMRD) syndrome. (10th September 2017)

• Record Type: Journal Article
• Authors: Westdorp, Harm; Kolders, Sigrid; Hoogerbrugge, Nicoline; de Vries, I. Jolanda M.; Jongmans, Marjolijn C.J.; Schreibelt, Gerty
• Is Part Of: Cancer letters. Volume 403(2017)
• Page Start: 159
• Page End: 164
• Publication Date: 2017-09-10
• Subjects: Constitutional mismatch repair deficiency syndrome -- CMMRD -- Neoantigens -- Cancer immunotherapy -- Prevention; CMMRD constitutional mismatch repair deficiency -- COX cyclooxygenase -- CRC colorectal cancer -- CTLs cytotoxic T lymphocytes -- GBM glioblastoma multiforme -- LS Lynch syndrome -- MMR mismatch repair -- MSI microsatellite instability -- Tregs regulatory T cells; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Electronic journals; 616.994
• DOI: 10.1016/j.canlet.2017.06.018
• Languages: English
• ISSNs: 0304-3835

Abstract

Abstract: Monoallelic germline mutations in one of the DNA mismatch repair (MMR) genes cause Lynch syndrome, with a high lifetime risks of colorectal and endometrial cancer at adult age. Less well known, is the constitutional mismatch repair deficiency (CMMRD) syndrome caused by biallelic germline mutations in MMR genes. This syndrome is characterized by the development of childhood cancer. Patients with CMMRD are at extremely high risk of developing multiple cancers including hematological, brain and intestinal tumors. Mutations in MMR genes impair DNA repair and therefore most tumors of patients with CMMRD are hypermutated. These mutations lead to changes in the translational reading frame, which consequently result in neoantigen formation. Neoantigens are recognized as foreign by the immune system and can induce specific immune responses. The growing evidence on the clinical efficacy of immunotherapies, such as immune checkpoint inhibitors, offers the prospect for treatment of patients with CMMRD. Combining neoantigen-based vaccination strategies and immune checkpoint inhibitors could be an effective way to conquer CMMRD-related tumors. Neoantigen-based vaccines might also be a preventive treatment option in healthy biallelic MMR mutation carriers. Future studies need to reveal the safety and efficacy of immunotherapies for patients with CMMRD. Highlights: CMMRD is a cancer predisposition syndrome with a high mortality rate. Cancer immunotherapy can be used as a strategy to elicit a potent antitumor immune response. Future research is needed to investigate the effects and risks of these therapies in CMMRD.